文献速递创伤与烧伤复苏、休克与脓毒症

院前氨甲环酸对出血性创伤患者死亡率的影响:系统评价与Meta分析

The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论院前氨甲环酸可显著降低疑似或确诊出血创伤患者的24小时死亡率(OR 0.60,95%CI 0.37-0.99),且不增加静脉血栓栓塞症发生率。

该系统评价与Meta分析检索EMBASE、Medline、PubMed等数据库,纳入4项研究(3项观察性队列和1项随机对照试验),共2,347例患者(氨甲环酸组1,169例 vs 无氨甲环酸组1,178例)。结果显示,院前氨甲环酸组24小时死亡率显著降低(OR 0.60,95%CI 0.37-0.99),28-30天死亡率(OR 0.69,95%CI 0.47-1.02)和静脉血栓栓塞症(OR 1.49,95%CI 0.90-2.46)无统计学显著差异。结论认为院前氨甲环酸与早期(24小时)死亡率显著降低相关,且不增加静脉血栓栓塞症发生率。证据等级为Level I。

要点

  • 院前氨甲环酸显著降低出血创伤患者24小时死亡率(OR 0.60,95%CI 0.37-0.99)。
  • 28-30天死亡率无统计学显著差异(OR 0.69,95%CI 0.47-1.02)。
  • 静脉血栓栓塞症风险无统计学显著增加(OR 1.49,95%CI 0.90-2.46)。
  • 共纳入4项研究(3项队列+1项RCT),2,347例患者(氨甲环酸组1,169例 vs 无氨甲环酸组1,178例)。

适用人群与场景

  • 疑似或确诊出血的创伤患者,接受院前救治。

研究设计与关键结果

  • 系统评价与Meta分析,纳入4项研究(3项观察性队列和1项随机对照试验),共2,347例患者(氨甲环酸组1,169例 vs 无氨甲环酸组1,178例)。
  • 院前氨甲环酸组24小时死亡率显著降低,OR 0.60(95%CI 0.37-0.99)。
  • 28-30天死亡率无统计学显著差异,OR 0.69(95%CI 0.47-1.02)。
  • 静脉血栓栓塞症无统计学显著差异,OR 1.49(95%CI 0.90-2.46)。

证据类型、等级与局限

  • 系统评价与Meta分析,证据等级Level I。
  • 纳入研究包括3项观察性队列研究和1项随机对照试验。
  • 使用Cochrane偏倚风险评估工具(随机对照试验)和Newcastle-Ottawa量表(队列观察性研究)进行质量评价。

对床旁实践的改变

  • 作者认为院前氨甲环酸与创伤出血患者早期(24小时)死亡率显著降低相关,且不增加静脉血栓栓塞症发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tranexamic acid (TXA) is an antifibrinolytic drug associated with improved survival among trauma patients with hemorrhage. Tranexamic acid is considered a primary hemostatic intervention in prehospital for treatment of bleeding alongside blood product transfusion.

METHODS: A systematic review and meta-analysis was conducted to investigate the impact of prehospital TXA on mortality among trauma patients with bleeding. A systematic search was conducted using the National Institute for Health and Care Excellence Healthcare Databases Advanced Search library which contain the following of databases: EMBASE, Medline, PubMed, BNI, EMCARE, and HMIC. Other databases searched included SCOPUS and the Cochrane Central Register for Clinical Trials Library. Quality assessment tools were applied among included studies; Cochrane Risk of Bias for randomized control trials and Newcastle-Ottawa Scale for cohort observational studies.

RESULTS: A total of 797 publications were identified from the initial database search. After removing duplicates and applying inclusion/exclusion criteria, four studies were included in the review and meta-analysis which identified a significant survival benefit in patients who received prehospital TXA versus no TXA. Three observational cohort and one randomized control trial were included into the review with a total of 2,347 patients (TXA, 1,169 vs. no TXA, 1,178). There was a significant reduction in 24 hours mortality; odds ratio (OR) of 0.60 (95% confidence interval [CI], 0.37-0.99). No statistical significant differences in 28 days to 30 days mortality; OR of 0.69 (95% CI, 0.47-1.02), or venous thromboembolism OR of 1.49 (95% CI, 0.90-2.46) were found.

CONCLUSION: This review demonstrates that prehospital TXA is associated with significant reductions in the early (24 hour) mortality of trauma patients with suspected or confirmed hemorrhage but no increase in the incidence of venous thromboembolism.

LEVEL OF EVIDENCE: Systematic review and meta-analysis. Level I.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Almuwallad A, Cole E, Ross J, et al. The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2021. PMID: 33605702. doi:10.1097/TA.0000000000003120

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。